Clinical Trials Browser

Phase 1/2 × Inflammatory Breast Neoplasms × tipifarnib × Clear all

NCT00070252 2015-05-04

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms